

Richard K Bogan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/977828/publications.pdf>

Version: 2024-02-01

29
papers

661
citations

933447

10
h-index

642732

23
g-index

30
all docs

30
docs citations

30
times ranked

487
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. <i>Lancet Neurology</i> , The, 2022, 21, 53-65.	10.2	37
2	Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy. <i>Nature and Science of Sleep</i> , 2022, Volume 14, 531-546.	2.7	3
3	Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial. <i>CNS Drugs</i> , 2022, 36, 377-387.	5.9	8
4	Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticatataplectic Medications. <i>CNS Drugs</i> , 2022, 36, 633-647.	5.9	7
5	0401 Efficacy of Once-Nightly Sodium Oxybate (ON-SXB; FT218) By Narcolepsy Type: Post-hoc Analyses From the REST-ON Trial. <i>Sleep</i> , 2022, 45, A179-A180.	1.1	0
6	0408 A Narcolepsy Detection Paradigm: Automated Nocturnal Detection and Notification of Sleep Onset Rapid Eye Movement Periods. <i>Sleep</i> , 2022, 45, A182-A183.	1.1	0
7	0386 Long-term Safety During a Clinical Trial of Lower-Sodium Oxybate in Participants With Narcolepsy With Cataplexy. <i>Sleep</i> , 2022, 45, A173-A173.	1.1	1
8	0406 Efficacy of Once-Nightly Sodium Oxybate (ON-SXB; FT218) Across Stimulant Use Subgroups: Post-hoc Analyses From the REST-ON Trial. <i>Sleep</i> , 2022, 45, A182-A182.	1.1	0
9	Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate) in narcolepsy with cataplexy. <i>Sleep</i> , 2021, 44, .	1.1	39
10	487 Effect of Lower-Sodium Oxybate on Sleep Inertia in Idiopathic Hypersomnia in a Double-Blind, Randomized Withdrawal Study. <i>Sleep</i> , 2021, 44, A192-A192.	1.1	0
11	491 Efficacy of FT218, a Once-Nightly Sodium Oxybate Formulation, by Narcolepsy Subtype: A Post Hoc Analysis From the REST-ON Study. <i>Sleep</i> , 2021, 44, A194-A194.	1.1	0
12	493 Weight Loss With FT218, a Once-Nightly Sodium Oxybate Formulation for the Treatment of Narcolepsy: Post Hoc Analysis From REST-ON. <i>Sleep</i> , 2021, 44, A194-A195.	1.1	0
13	492 Efficacy of FT218, a Once-Nightly Sodium Oxybate Formulation, by Stimulant Use: A Post Hoc Analysis From the REST-ON Study. <i>Sleep</i> , 2021, 44, A194-A194.	1.1	0
14	494 Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia. <i>Sleep</i> , 2021, 44, A195-A195.	1.1	1
15	486 Timing and Duration of Adverse Events in a Clinical Trial of Lower-Sodium Oxybate in Participants With Narcolepsy With Cataplexy. <i>Sleep</i> , 2021, 44, A192-A192.	1.1	2
16	Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. <i>Sleep Medicine</i> , 2020, 68, 97-109.	1.6	53
17	Longitudinal study of narcolepsy symptoms in first, second, and third-degree relatives of simplex and multiplex narcolepsy families. <i>Sleep Medicine</i> , 2019, 53, 88-93.	1.6	4
18	<p>The SinuSonic: reducing nasal congestion with acoustic vibration and oscillating expiratory pressure</p>. <i>Medical Devices: Evidence and Research</i> , 2019, Volume 12, 305-310.	0.8	3

#	ARTICLE	IF	CITATIONS
19	O656 Validation of the Self-administered Version of the International Restless Legs Syndrome Study Group Severity Rating Scale - the sIRLS. <i>Sleep</i> , 2019, 42, A261-A262.	1.1	1
20	Validation of the self-administered version of the international Restless Legs Syndrome study group severity rating scale " The sIRLS. <i>Sleep Medicine</i> , 2019, 54, 94-100.	1.6	34
21	Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1421-1431.	5.6	272
22	Correlation of Changes in Patient-Reported Quality of Life With Physician-Rated Global Impression of Change in Patients With Narcolepsy Participating in a Clinical Trial of Sodium Oxybate: A Post Hoc Analysis. <i>Neurology and Therapy</i> , 2017, 6, 237-245.	3.2	7
23	Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes. <i>Sleep Medicine</i> , 2017, 35, 12-16.	1.6	7
24	A Randomized Crossover Trial of a Pressure Relief Technology (SensAwake,®) in Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea. <i>Sleep Disorders</i> , 2017, 2017, 1-6.	1.4	10
25	Sex differences in sleep apnea predictors and outcomes from home sleep apnea testing. <i>Nature and Science of Sleep</i> , 2016, Volume 8, 197-205.	2.7	24
26	Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. <i>Sleep Medicine</i> , 2016, 24, 57-62.	1.6	26
27	Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. <i>Sleep Medicine</i> , 2015, 16, 1102-1108.	1.6	64
28	Time to Response with Sodium Oxybate for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 427-432.	2.6	37
29	Armodafinil in the treatment of excessive sleepiness. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 993-1002.	1.8	18